Harald Reinhart
InvestorVenture Partner at Quan Capital
About
Dr. Harald Reinhart joined Quan Capital as a Venture Partner in 2025 and is CEO of Allphase Pharma Consulting LLC, as well as Adjunct Clinical Professor of infectious diseases at Yale School of Medicine. Before retiring in 2024, he led Global Development for Neuroscience, Autoimmune and Infectious Diseases at Zai Lab, and previously held clinical development roles at Shionogi US, Novartis, and Bayer, working on approvals for compounds including ospemifene, Coartem, Famvir, Sebivo, and Cubicin. He holds a medical degree from the University of Würzburg and is board-certified in internal medicine and infectious diseases.
Invests in
Biotech
Colleagues at Quan Capital
Angela Shen
Senior Advisor at Quan Capital
Cherry Jin
Executive Assistant at Quan Capital
Crystal Yin
Director, Finance at Quan Capital
John Wong
Venture Partner at Quan Capital
Kui Wang
Senior Associate at Quan Capital
Lena Guo
Operation Manager at Quan Capital
Marietta Wu
Managing Director at Quan Capital
Peter Wirth
Senior Advisor at Quan Capital
Frequently asked questions
- Who is Harald Reinhart?
- Dr. Harald Reinhart joined Quan Capital as a Venture Partner in 2025 and is CEO of Allphase Pharma Consulting LLC, as well as Adjunct Clinical Professor of infectious diseases at Yale School of Medicine. Before retiring in 2024, he led Global Development for Neuroscience, Autoimmune and Infectious Diseases at Zai Lab, and previously held clinical development roles at Shionogi US, Novartis, and Bayer, working on approvals for compounds including ospemifene, Coartem, Famvir, Sebivo, and Cubicin. He holds a medical degree from the University of Würzburg and is board-certified in internal medicine and infectious diseases.
- Where does Harald Reinhart work?
- Harald Reinhart is Venture Partner at Quan Capital.
- What does Harald Reinhart invest in?
- Harald Reinhart invests in Biotech.